Home » Stocks » VOR

Vor Biopharma, Inc. (VOR)

Stock Price: $33.37 USD -0.33 (-0.98%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $33.70 +0.33 (0.99%) Mar 5, 4:55 PM
Market Cap 1.24B
Revenue (ttm) n/a
Net Income (ttm) -31.57M
Shares Out 35.29M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $33.37
Previous Close $33.70
Change ($) -0.33
Change (%) -0.98%
Day's Open 34.24
Day's Range 30.17 - 36.53
Day's Volume 352,930
52-Week Range 25.32 - 63.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted t...

GlobeNewsWire - 5 days ago

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted t...

GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted th...

GlobeNewswire - 1 month ago

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced...

NASDAQ - 1 month ago

Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

SEC - 1 month ago

Vor Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

Healio - 1 month ago

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, a...

About VOR

Vor Biopharma is a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT). Despite undergoing HSCT, approximately 40% of acute myeloid leukemia (AML) patients relapse and face an extremely poor prognosis, with two-year survival rates of less than 20%. The traditional tumor target ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Robert Ang, M.B.B.S.
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
VOR
Full Company Profile

Financial Performance

Financial Statements